Patents Assigned to Alcon
  • SELF-COMPLEMENTARY AAV-MEDIATED DELIVERY OF INTERFERING RNA MOLECULES TO TREAT OR PREVENT OCULAR DISORDERS
    Publication number: 20090087413
    Abstract: The invention provides methods for delivering interfering RNA molecules to an eye of a patient to treat ocular disorders. In particular, the methods of the invention comprise the use of a self-complementary adeno-associated (scAAV) viral vector that can deliver an interfering RNA molecule to an eye of a patient to inhibit expression of a gene that is associated with an ocular disorder.
    Type: Application
    Filed: October 1, 2008
    Publication date: April 2, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventor: Allan R. Shepard
  • OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS CONTAINING AN ALKYLPHENOL ETHOXYLATE
    Publication number: 20090088493
    Abstract: Disclosed are soft, high refractive index, acrylic device materials. The materials contain a functionalized alkylphenol ethoxylate to reduce glistenings.
    Type: Application
    Filed: October 1, 2008
    Publication date: April 2, 2009
    Applicant: ALCON, INC.
    Inventors: Water R. Laredo, Douglas C. Schlueter
  • OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS CONTAINING AN ALKYL ETHOXYLATE
    Publication number: 20090088544
    Abstract: Disclosed are soft, high refractive index, acrylic device materials. The materials contain a functionalized alkyl ethoxylate to reduce glistenings.
    Type: Application
    Filed: October 1, 2008
    Publication date: April 2, 2009
    Applicant: ALCON, INC.
    Inventor: Walter R. Laredo
  • Method for determining a pressure that corresponds to a flow rate through a check valve
    Patent number: 7509831
    Abstract: The present invention accommodates differences in cracking pressures between check valves by determining a pressure on the input of a check valve that corresponds to a predetermined flow rate at the output of the check valve. A container is incrementally pressurized and the vacuum at a point on the output side of the check valve is monitored. Once fluid begins to pass through the check valve, the vacuum drops. At the predetermined flow rate, the pump cannot maintain a predetermined vacuum level since it cannot exceed a maximum speed. At this point the pressure applied to the container corresponds to the predetermined flow rate. An offset is added to the pressure to determine the minimum operating pressure.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: March 31, 2009
    Assignee: Alcon, Inc.
    Inventor: Amir H. Khashayar
  • Ophthalmic Endoilluminator with Variable-Wedge Rotating-Disk Beam Attenuator
    Patent number: 7499624
    Abstract: An ophthalmic endoilluminator includes a light source, a variable-wedge rotating-disk attenuator, a condensing lens, and an optical fiber. The variable-wedge rotating-disk attenuator attenuates the light produced by the light source. The variable-wedge rotating-disk attenuator includes a wedge capable of being adjusted over a variable angle as measured through an arc of the wedge and an axle to which the wedge is attached. The axle rotates such that the wedge rotates around a pivot defined by the axle. The condensing lens focuses the attenuated light. The optical fiber carries the focused light into an eye. The variable-wedge rotating-disk attenuator is located such that it affects the intensity of a light beam transmitted into an eye.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: March 3, 2009
    Assignee: Alcon, Inc.
    Inventors: Bruno Dacquay, John C. Huculak, Ron T. Smith
  • RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF OCULAR NEOVASCULARIZATION
    Publication number: 20090054365
    Abstract: RNA interference is provided for inhibition of aquaporin 1 (AQP1) to treat conditions associated with neovascularization.
    Type: Application
    Filed: January 28, 2008
    Publication date: February 26, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Rajkumar V. Patil, Jon E. Chatterton, Najam A. Sharif, Martin B. Wax
  • USE OF AGENTS THAT UPREGULATE CRYSTALLIN EXPRESSION IN THE RETINA AND OPTIC NERVE HEAD
    Publication number: 20090048146
    Abstract: The present invention relates to methods to treat and/or prevent optic nerve damage in a subject by administering a composition comprising a crystallin agonist.
    Type: Application
    Filed: December 21, 2007
    Publication date: February 19, 2009
    Applicant: ALCON, INC.
    Inventors: Abot F. Clark, John C. Morrison, Elaine C. Johnson
  • OPHTHALMIC LENS MATERIALS CONTAINING CHROMOPHORES THAT ABSORB BOTH UV AND SHORT WAVELENGTH VISIBLE LIGHT
    Publication number: 20090043007
    Abstract: Chromophores that absorb both UV and short wavelength visible light are disclosed. The chromophores are particularly suitable for use in intraocular lens materials.
    Type: Application
    Filed: August 7, 2008
    Publication date: February 12, 2009
    Applicant: ALCON, INC.
    Inventors: Joseph I. Weinschenk, III, Douglas C. Schlueter, David L. Jinkerson
  • OPHTHALMIC LENS MATERIALS CONTAINING CHROMOPHORES THAT ABSORB BOTH UV AND SHORT WAVELENGTH VISIBLE LIGHT
    Publication number: 20090043105
    Abstract: Chromophores that absorb both UV and short wavelength visible light are disclosed. The chromophores are particularly suitable for use in intraocular lens materials.
    Type: Application
    Filed: August 7, 2008
    Publication date: February 12, 2009
    Applicant: ALCON, INC.
    Inventors: Joseph I. Weinschenk, III, Douglas C. Schlueter, David L. Jinkerson
  • High Refractive Index Ophthalmic Device Materials
    Publication number: 20090043006
    Abstract: High refractive index copolymers suitable for use in ophthalmic devices are disclosed. The copolymers comprise two or more aryl hydrophobic monomers and a non-polymerizable propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having a molecular weight of approximately 3600 and approximately 40% ethylene oxide units by weight. The copolymers have a reduced tendency to form glistenings when stored in water at physiological temperatures compared to similar copolymers lacking the non-polymerizable surfactant.
    Type: Application
    Filed: July 24, 2008
    Publication date: February 12, 2009
    Applicant: ALCON, INC.
    Inventor: Charles Freeman
  • Use of non-feminizing estrogens as treatment for retinal vascular diseases
    Patent number: 7488723
    Abstract: The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal vascular diseases.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: February 10, 2009
    Assignee: Alcon, Inc.
    Inventor: Iok-Hou Pang
  • RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA
    Publication number: 20090036397
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having or at risk of developing macular edema.
    Type: Application
    Filed: August 4, 2008
    Publication date: February 5, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
    Publication number: 20090035225
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 5, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents
    Publication number: 20090036371
    Abstract: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.
    Type: Application
    Filed: February 27, 2008
    Publication date: February 5, 2009
    Applicant: ALCON, INC.
    Inventors: Abbot F. CLARK, Wan-Heng WANG, Loretta MCNATT
  • RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20090036396
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 5, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • Compositions and methods for inhibiting protein on surfaces
    Patent number: 7485607
    Abstract: The use of NIPAM polymers to prevent or reduce the formation of protein deposits on the surfaces of medical devices is described. The invention is particularly directed to reduction of the adsorption of proteins on surfaces of contact lenses and other medical prosthetics.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: February 3, 2009
    Assignee: Alcon, Inc.
    Inventor: Howard Allen Ketelson
  • Connector to cassette interface system
    Patent number: 7484769
    Abstract: The disclosed connector to cassette interface system includes a set of individual keyed connectors having a shroud on the lower portion. The perimeter of each shroud includes an array of tabs or protrusions keyed to one of a corresponding array of skirted portals in the cassette cover. The tabs or protrusions on the shroud portion of each individual keyed connector may further serve to prevent rotation of each connector beyond about 60°.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: February 3, 2009
    Assignee: Alcon, Inc.
    Inventors: David M. Domash, James J. Foster
  • USE OF BIS-AMINES TO ENHANCE THE ANTIMICROBIAL ACTIVITY OF AQUEOUS COMPOSITIONS
    Publication number: 20090030085
    Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.
    Type: Application
    Filed: October 3, 2008
    Publication date: January 29, 2009
    Applicant: ALCON, INC.
    Inventors: Nissanke L. Dassanayake, Thomas Christopher Carey, Ronald L. Schlitzer, David L. Meadows
  • Pseudo-accommodative IOL having multiple diffractive patterns
    Patent number: 7481532
    Abstract: In one aspect, a trifocal ophthalmic lens is disclosed that includes an optic having a surface that comprises at least one trifocal diffractive pattern and at least one bifocal diffractive pattern such that the bifocal pattern provides near and far vision and the trifocal pattern generates near, far, and intermediate vision. For example, the trifocal pattern can provide near, far, and intermediate foci such that the near and far foci are substantially coincident, respectively, with a near and a far focus of the bifocal pattern. In this manner, the trifocal and bifocal patterns collectively provide near, intermediate, and far foci (or focal regions) corresponding, respectively, to the near, intermediate and far vision.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: January 27, 2009
    Assignee: Alcon, Inc.
    Inventors: Xin Hong, Steve VanNoy, Xiaoxiao Zhang
  • High Ion And Metabolite Flux Lenses And Materials
    Publication number: 20090023835
    Abstract: An exemplary embodiment provides a biocompatible polymer composition suitable for making intraocular lenses, especially posterior chamber phakic lenses, that includes a hydrogel having an equilibrium water content of less than about 55 wt. %. The hydrogel has a refractive index greater than about 1.41 and a sodium ion flux between about 16 to about 20 ?eq-mm/hr/cm2.
    Type: Application
    Filed: July 16, 2008
    Publication date: January 22, 2009
    Applicant: ALCON, INC.
    Inventor: Charles Freeman